LENVATINIB is a multiple-receptor tyrosine kinase (RTK) inhibitor that
- Inhibits the kinase activities of VEGF receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4)
- Also inhibits other RTKs implicated in pathogenic angiogenesis, tumor growth, and cancer progression, in addition to their normal functions, including
- FGF receptors FGFR1, 2, 3, and 4
- PDGFRα
- KIT
- RET
